Micafungin

ApprovedTerminated
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Candidemia

Conditions

Candidemia, Candidiasis

Trial Timeline

Sep 26, 2013 โ†’ Aug 28, 2015

About Micafungin

Micafungin is a approved stage product being developed by Astellas Pharma for Candidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01982071. Target conditions include Candidemia, Candidiasis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (15)

NCT IDPhaseStatus
NCT03174457Pre-clinicalCompleted
NCT03102658ApprovedCompleted
NCT02440178Phase 2Completed
NCT03421002Phase 2Completed
NCT02678598Pre-clinicalCompleted
NCT02127788Pre-clinicalCompleted
NCT02646800ApprovedTerminated
NCT02646774ApprovedTerminated
NCT02057289Phase 1Terminated
NCT01982071ApprovedTerminated
NCT01135589ApprovedUNKNOWN
NCT00606268Phase 1Completed
NCT00608335Phase 1Completed
NCT00818584Phase 1Completed
NCT00842504Phase 1Completed

Competing Products

9 competing products in Candidemia

See all competitors
ProductCompanyStageHype Score
micafungin + Micafungin + CaspofunginAstellas PharmaApproved
85
AmBisomeGilead SciencesApproved
84
Anidulafungin/FluconazolePfizerPhase 3
76
Anidulafungin + VoriconazolePfizerApproved
84
Anidulafungin + FluconazolePfizerPhase 3
76
AnidulafunginPfizerPhase 3
76
Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3
72
APX001Basilea PharmaceuticaPhase 2
47
APX001Basilea PharmaceuticaPhase 2
47